Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
About this item
Full title
Author / Creator
Publisher
Berlin/Heidelberg: Berlin/Heidelberg : Springer-Verlag
Journal title
Language
English
Formats
Publication information
Publisher
Berlin/Heidelberg: Berlin/Heidelberg : Springer-Verlag
Subjects
More information
Scope and Contents
Contents
Purpose Infliximab, a monoclonal antibody, is approved for the treatment of inflammatory diseases at doses that depend on the patient disease population. It was the aim of this study to evaluate its population pharmacokinetics in patients with moderately to severely active ulcerative colitis and characterize patient covariates that affect its dispo...
Alternative Titles
Full title
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2778780
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2778780
Other Identifiers
ISSN
0031-6970
E-ISSN
1432-1041
DOI
10.1007/s00228-009-0718-4
